Cargando…

Second-Generation Antipsychotics’ Effectiveness and Tolerability: A Review of Real-World Studies in Patients with Schizophrenia and Related Disorders

Despite methodological limitations, real-world studies might support clinicians by broadening the knowledge of antipsychotics’ (APs) effectiveness and tolerability in different clinical scenarios and complement clinical trials. We conducted an extensive literature search in the PubMed database to ev...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fabrazzo, Michele, Cipolla, Salvatore, Camerlengo, Alessio, Perris, Francesco, Catapano, Francesco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9369504/ https://www.ncbi.nlm.nih.gov/pubmed/35956145 http://dx.doi.org/10.3390/jcm11154530

Ejemplares similares

Delirium and Cognitive Impairment as Predisposing Factors of COVID-19 Infection in Neuropsychiatric Patients: A Narrative Review
por: Fabrazzo, Michele, et al.
Publicado: (2021)

Duration of Untreated Illness in Patients with Obsessive–Compulsive Disorder and Its Impact on Long-Term Outcome: A Systematic Review
por: Perris, Francesco, et al.
Publicado: (2023)

Vitamin D Deficiency and Risk Factors Related to Acute Psychiatric Relapses in Patients with Severe Mental Disorders: A Preliminary Study
por: Fabrazzo, Michele, et al.
Publicado: (2022)

Delirium and Psychiatric Sequelae Associated to SARS-CoV-2 in Asymptomatic Patients With Psychiatric History and Mild Cognitive Impairment as Risk Factors: Three Case Reports
por: Fabrazzo, Michele, et al.
Publicado: (2022)

Bipolar Patients and Bullous Pemphigoid after Risperidone Long-Acting Injectable: A Case Report and a Review of the Literature
por: Fabrazzo, Michele, et al.
Publicado: (2021)

Comorbidity of Obsessive-Compulsive Disorder and Schizotypal Personality Disorder: Clinical Response and Treatment Resistance to Pharmacotherapy in a 3-Year Follow-Up Naturalistic Study
por: Perris, Francesco, et al.
Publicado: (2019)

Efficacy and Tolerability of Second-Generation Antipsychotics in Children and Adolescents With Schizophrenia
por: Kumra, Sanjiv, et al.
Publicado: (2008)

A systematic review on shared biological mechanisms of depression and anxiety in comorbidity with psoriasis, atopic dermatitis, and hidradenitis suppurativa
por: Fabrazzo, Michele, et al.
Publicado: (2021)

Organizational and Individual Interventions for Managing Work-Related Stress in Healthcare Professionals: A Systematic Review
por: Catapano, Pierluigi, et al.
Publicado: (2023)

Weight gain and comorbidities associated with oral second-generation antipsychotics: analysis of real-world data for patients with schizophrenia or bipolar I disorder
por: Doane, Michael J., et al.
Publicado: (2022)

Adherence and Continuation of Treatment with First- and Second-generation Antipsychotics in Schizophrenia
por: Warikoo, Nisha, et al.
Publicado: (2014)

Updating the Comparative Evidence on Second‐Generation Antipsychotic Use With Schizophrenia
por: McDonagh, Marian S., et al.
Publicado: (2020)

The Use of Second-Generation Antipsychotics in Patients with Severe Schizophrenia in the Real World: The Role of the Route of Administration and Dosage—A 5-Year Follow-Up
por: Fernández-Miranda, Juan J., et al.
Publicado: (2022)

Comparative study of treatment continuation using second-generation antipsychotics in patients with schizophrenia or schizoaffective disorder
por: Azekawa, Takaharu, et al.
Publicado: (2011)

Pharmacogenetics and Schizophrenia—Can Genomics Improve the Treatment with Second-Generation Antipsychotics?
por: Płaza, Olga, et al.
Publicado: (2022)

Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review
por: Solmi, Marco, et al.
Publicado: (2017)

Relapse Prevention in Schizophrenia: A Systematic Review and Meta-Analysis of Second-Generation Antipsychotics versus First-Generation Antipsychotics
por: Kishimoto, Taishiro, et al.
Publicado: (2011)

Does Vitamin D matter? The role of calcium homeostasis imbalance in clinical severity of psychiatric patients
por: Altucci, G., et al.
Publicado: (2022)

Real-World Patterns of Utilization and Costs Associated with Second-Generation Oral Antipsychotic Medication for the Treatment of Bipolar Disorder: A Literature Review
por: Doane, Michael J, et al.
Publicado: (2021)

Attitudes Towards Antipsychotics Among Patients with Schizophrenia on First- or Second-Generation Medications
por: Karthik, M. S., et al.
Publicado: (2014)

Use of second-generation antipsychotics in the acute inpatient management of schizophrenia in the Middle East
por: Alkhadhari, Sulaiman, et al.
Publicado: (2015)

Switching Between Second-Generation Antipsychotics in Patients with Schizophrenia and Schizoaffective Disorder: 10-Year Cohort Study in Brazil
por: Fulone, Izabela, et al.
Publicado: (2021)

Second Generation Antipsychotics in the Treatment of Major Depressive Disorder: An Update
por: Wang, Sheng-Min, et al.
Publicado: (2016)

Drug-emergent metabolic syndrome in patients with schizophrenia receiving atypical (second-generation) antipsychotics
por: Gautam, Shiv, et al.
Publicado: (2011)

Second Generation Antipsychotics Improve Sexual Dysfunction in Schizophrenia: A Randomised Controlled Trial
por: Mahmoud, Ahmed, et al.
Publicado: (2011)

Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life
por: Montemagni, Cristiana, et al.
Publicado: (2016)

Simultaneous Comparison of Efficacy and Tolerability of Second-Generation Antipsychotics in Schizophrenia: Mixed-Treatment Comparison Analysis Based on Head-to-Head Trial Data
por: Oh, Gyu Han, et al.
Publicado: (2015)

Real‐world effectiveness of antipsychotics
por: Tiihonen, J.
Publicado: (2016)

Preexisting mild cognitive impairment as a risk factor for COVID-19 infection: A scoping review and case reports
por: Catapano, P., et al.
Publicado: (2022)

Efficacy and tolerance of second-generation antipsychotics in anorexia nervosa: A systematic scoping review
por: Thorey, Solène, et al.
Publicado: (2023)

Long-Term Evolution of Metabolic Status in Patients with Schizophrenia Stably Maintained on Second-Generation Antipsychotics
por: Jeong, Seong Hoon, et al.
Publicado: (2018)

Association between IL-6 and metabolic syndrome in schizophrenia patients treated with second-generation antipsychotics
por: Fang, Xinyu, et al.
Publicado: (2019)

Effects of the combination of second-generation antipsychotics on serum concentrations of aripiprazole and dehydroaripiprazole in Chinese patients with schizophrenia
por: Jiang, Ping, et al.
Publicado: (2021)

Controversies in bipolar disorder; role of second-generation antipsychotic for maintenance therapy
por: Jauhar, Sameer, et al.
Publicado: (2019)

Association of Lithium and Second-Generation Antipsychotics with Neurocognition in Youth with Bipolar Disorder
por: Jiang, Xinyue, et al.
Publicado: (2022)

Adherence to oral second-generation antipsychotic medications in patients with schizophrenia and bipolar disorder: physicians’ perceptions of adherence vs. pharmacy claims
por: Stephenson, J J, et al.
Publicado: (2012)

Quantitative efficacy of three antipsychotic drugs for schizophrenia based on a real-world study in China
por: Zhang, Lei, et al.
Publicado: (2019)

A Real-World Observation of Antipsychotic Effects on Brain Volumes and Intrinsic Brain Activity in Schizophrenia
por: Chen, Yifan, et al.
Publicado: (2022)

Long-acting Injectable Antipsychotics during the COVID-19 pandemic in schizophrenia: An observational study in a real-world clinical setting
por: Barlati, Stefano, et al.
Publicado: (2022)

Dopamine, Cognitive Impairments and Second-Generation Antipsychotics: From Mechanistic Advances to More Personalized Treatments
por: Torrisi, Sebastiano Alfio, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ki2tdp61n95btqtm6kqr54kr17